Outlook Therapeutics, Inc. (OTLK)

NASDAQ: OTLK · USD

$0.46

-0.01 (-2.0%)· Recorded snapshot

Market cap	112M
Revenue (ttm)	-1.2M
Net income (ttm)	-61.1M
EPS (ttm)	-$0.75
Shares out	243.4M
Volume	2,519,262.58
Beta	0.67

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): -1.2M
Net income (ttm): -61.1M
EPS (ttm): -$0.75
Market cap: 112M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Manter

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-1,253.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All OTLK indicators

Market & fundamental data

Available fields

191

Groups with data

Currency

USD

Showing 191 of 191 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001649989
Company name	Outlook Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	69012T305
Earnings date	2026-12-18
Earnings time	bmo
Employees	17
Employees change	-6
Employees growth	-26.09%
Enterprise value	$119.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	September
Founded	2010
Industry	Biotechnology
IPO date	2016-05-13
Is primary listing	Yes
Is SPAC	No
ISIN number	US69012T3059
Last 10-K release date	2025-12-19
Last earnings date	2026-08-14
Last refreshed	2026-11-04
Last stock split date	2024-03-14
Last stock split type	Reverse
Market cap	$112M
Market cap category	Micro-Cap
Next earnings date	2026-12-18
Options	Yes
Price	$0.46
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-03
Symbol	OTLK
U.S. state	New Jersey
Website	https://outlooktherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-162.6%
FCF / EV yield	-47.12%
FCF yield	-50.14%
Forward EV/Sales	4.32x
Forward P/S	4.06x
Sector forward P/E	23.49x
Sector P/E	49.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	4,781.84%
Pretax margin	5,387.1%
Profit per employee	$-3.6M
ROA	-143.17%
ROA (5Y)	-147.64%
ROCE	2,230.6%
ROIC	-1,253.84%
SBC / revenue	-365.36%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	10
Net income growth years	1
Revenue growth (Q)	-99.42%
Revenue growth (QoQ)	-93.17%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$104,019
EBIT	$-55.6M
EBITDA	$-55.5M
EPS	$-0.75
FCF per share	$-0.23
Financing cash flow	$60.6M
Free cash flow	$-56.2M
Free cash flow minus SBC	$-60.4M
Gross profit	$-2.3M
Income taxes	$-1.6M
Investing cash flow	$-2.1M
Net borrowing	$-2.3M
Net cash flow	$2.3M
Net income	$-61.1M
Operating cash flow minus SBC	$-60.4M
Operating income	$-55.6M
Revenue	$-1.2M
Stock-based compensation	$4.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-41.12
Book value per share	$-0.06
Interest coverage	-210.62
Long-term assets	$3M
Long-term liabilities	$7.9M
Net cash (debt)	$-7.2M
Net cash / market cap	-6.42%
Piotroski F-Score	3
Property, plant and equipment	$185,183
Shareholders' equity	$-10.4M
Tangible book value	$-10.4M
Tangible book value per share	$-0.06
Total assets	$26.2M
Total cash	$11.2M
Total debt	$18.4M
Total liabilities	$36.6M
WACC	6.99%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$23.2M
Current liabilities	$28.7M
Current ratio	0.81
Inventory turnover	0.24
Net working capital	$1.5M
Quick ratio	0.45
Working capital	$-5.5M
Working capital turnover	0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-182.49%
Dividend yield	0%
Shareholder yield	-182.49%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.93%
10Y return CAGR	-51.63%
10Y total return	-99.93%
150-day SMA	$0.75
1D price change	-1.96%
1M price change	-22.43%
1M total return	-22.43%
1W price change	-13.17%
1W total return	-13.17%
1Y price change	-63.49%
1Y return CAGR	-63.52%
1Y total return	-63.49%
20-day SMA	$0.52
200-day SMA	$0.66
3M price change	-52.9%
3M total return	-52.9%
3Y price change	-93.24%
3Y return CAGR	-59.25%
3Y total return	-93.24%
50-day SMA	$0.59
50-day SMA vs 200-day SMA	50under200
52-week high	$2.54
52-week high date	2025-12-17
52-week low	$0.16
52-week low date	2026-03-24
5Y price change	-98.9%
5Y return CAGR	-59.42%
5Y total return	-98.9%
6M price change	75.44%
6M total return	75.44%
After-hours change	1.96%
After-hours close	$0.46
After-hours price	$0.47
All-time high	$878.40
All-time high date	2016-09-01
All-time low	$0.16
All-time low date	2026-03-24
Average true range (ATR)	$0.05
Average volume	3.8M
Beta (1Y)	3.39
Beta (2Y)	1.83
Beta (5Y)	0.67
Change from 52-week high	-81.88%
Change from 52-week low	185.54%
Change from all-time high	-99.95%
Change from all-time low	185.54%
Change from open	-0.54%
Day's gap	-1.43%
Dollar volume	$1.2M
High price	$0.48
Low price	$0.45
Monthly RSI	36.88
Open price	$0.46
Position in 52-week range	28.78%
Premarket change	0%
Premarket close	$0.46
Premarket price	$0.46
Previous close	$0.47
Price vs 150-day SMA	-38.56%
Price vs 20-day SMA	-12.35%
Price vs 200-day SMA	-30.51%
Price vs 50-day SMA	-22.47%
Relative volume	0.66
RSI	35.17
Sharpe ratio	0.13
Sharpe ratio (3Y)	-0.07
Sharpe ratio (5Y)	-0.03
Sortino ratio	0.23
Sortino ratio (3Y)	-0.05
Sortino ratio (5Y)	0
Volume	2.5M
Weekly RSI	39.38
YTD price change	-70.89%
YTD total return	-70.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	176.6M
Float percentage	72.53%
Shares change (QoQ)	67.09%
Shares change (YoY)	182.49%
Shares held by insiders	0.42%
Shares held by institutions	21.43%
Shares outstanding	243.4M
Short % of float	18.46%
Short % of shares	13.39%
Short ratio	7 days

Deeper analysis on OTLK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this OTLK report

Is a complete OTLK research report available?

No complete published report is available for Outlook Therapeutics, Inc. (OTLK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Outlook Therapeutics, Inc. (OTLK)

Price

Financial snapshot

Fair-value bridge

Latest news · OTLK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All OTLK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on OTLK

Frequently asked questions